Baxter International Inc.

Deerfield, Illinois, USA

35,858 Total Employees

Year Founded: 1931

View Website

Baxter International Inc. Company Stability & Growth

Updated on January 08, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for Baxter International Inc.?

Strengths in core hospital categories and an active product refresh underpin Baxter’s positioning, while portfolio refocus and leadership changes signal a forward-looking strategy. At the same time, GAAP losses, supply-chain and quality disruptions, and muted organic growth temper resilience, suggesting a cautious outlook where execution and supply stability will determine the durability of improvement.

Positive Themes About Baxter International Inc.

Strong Market Position & Advantage: Baxter is a leader in U.S. IV solutions and a top contender in connected-care hospital beds and surgical hemostats, underscoring durable share in core hospital categories. This positioning supports resilience despite category- and region-specific competition.
Product Line Growth: Ongoing updates to infusion technologies and continued launches in injectables and advanced surgery indicate a healthy product refresh cadence. FDA clearances and connected-care enhancements help sustain installed-base momentum.
Future-Ready Strategy: Portfolio reshaping (Kidney Care divestiture) and new leadership focused on execution and continuous improvement signal a sharpened hospital-centric strategy. Deleveraging and supply-chain initiatives aim to improve stability and long-term growth capacity.

Considerations About Baxter International Inc.

Declining Profitability: GAAP losses in 2024 and in a recent quarter, alongside reliance on adjusted metrics, reflect margin pressure. Dividend reduction and ratings concerns highlight ongoing earnings and balance-sheet challenges.
Operational Inefficiency: Hurricane-related plant damage and the temporary pause of certain pump shipments exposed supply-chain concentration and quality/regulatory sensitivities. Recovery actions helped, but the events underscore execution risk in critical therapies.
Stagnant Revenue: Growth has been modest and uneven across segments and geographies, with downgraded full-year guidance and lingering IV-related softness. Multi-year comparisons are further complicated by portfolio changes, limiting clear top-line acceleration.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.

View All 177 Jobs at Baxter International Inc.

Is This Your Company? Claim Profile